Merrimack Pharmaceuticals (MACK) EBITDA (2012 - 2024)
Merrimack Pharmaceuticals (MACK) EBITDA from Mar 31, 2012 to Mar 31, 2024. The TTM Merrimack Pharmaceuticals (MACK) EBITDA is -$2.26M. You can adjust inflation or export chart.
Annual EBITDA
Quarterly EBITDA
Merrimack Pharmaceuticals (MACK) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +10.24% |
| 3 Years TTM | -16.12% |
| 5 Years TTM | -47.03% |
| 10 Years TTM | -32.44% |
| All Time TTM | -28.66% |
Annual EBITDA change of Merrimack Pharmaceuticals (MACK)
| Year | EBITDA | Change |
|---|---|---|
| 2024 | -$670K | -69.27% |
| 2023 | -$2.18M | +0.46% |
| 2022 | -$2.17M | -17.18% |
| 2021 | -$2.62M | -47.70% |
| 2020 | -$5.01M | -79.99% |
| 2019 | -$25M | -59.28% |
| 2018 | -$62M | -32.07% |
| 2017 | -$91M | -33.78% |
| 2016 | -$137M | -3.60% |
| 2015 | -$142M | +125.02% |
| 2014 | -$63M | -46.56% |
| 2013 | -$118M | +32.41% |
| 2012 | -$89M | N/A |